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approaches to identify small molecules that bind specific RNA secondary structure have had some success 8 , but achieving the desired selectivity and efficacy is difficult given the reoccurrence of secondary structural motifs across the transcriptome. While many RNA targets fold into unique 3D structures, application of structure-based approaches such as computational docking to identify compounds that specifically bind to these structures has been hampered by the high flexibility of RNA and its propensity to undergo large changes upon binding to small molecules that are difficult, if not impossible, to model computationally 9 .
Recently, hybrid experimental-computational approaches have been developed that enable the determination of dynamic ensembles of biomolecules at atomic resolution [10] [11] [12] [13] [14] [15] . The ensembles describe the different conformations sampled by a given biomolecule in solution. Studies on both proteins and nucleic acids have shown that conformations similar to those observed in ligand bound states are often significantly populated within the ensemble of unbound conformations [13] [14] [15] [16] . Inspired by these discoveries, we 9 and others 17 recently proposed to carry out EBVS by subjecting all conformers in experimentally determined ensembles to computational docking 9, 17 . Our approach was demonstrated using a dynamic ensemble of HIV-1 TAR 18 determined using two sets of NMR residual dipolar coupling (RDC) data and MD simulations 9, 13 . RDCs provide long-range information regarding the orientation of individual bond vectors in biomolecules relative to an alignment frame and are sensitive to internal motions spanning picosecond-to-millisecond timescales 19, 20 . EBVS was able to score a small set of 38 known TAR binders with an accuracy comparable to that obtained when docking 48 small molecules to their known bound RNA structure 9 . Experimentally testing the top 57 scoring small molecules out of a screen of 51,000 compounds yielded six hit molecules that bind TAR in vitro, including the first example of a small molecule that binds an RNA apical loop, and a highly selective compound that inhibits HIV replication in an HIV indicator cell line with IC 50 ∼20 µM 9 .
EBVS can in principle provide a basis for pre-screening compound libraries to enrich a subset of molecules with potentially active hits that specifically bind to the 3D structure(s) of an RNA target.
EBVS could also aid exploration of new regions of chemical space unhindered by physical constraints posed by existing libraries to identify novel RNA-binding scaffolds. To rigorously test the utility of EBVS in such pre-screening applications, we first generated a large dataset by subjecting HIV-1 TAR ( Fig. 1a ) to experimental HTS against ~100,000 drug-like organic molecules (Methods and Supplementary Fig. 1-4 ). This represents one of the largest RNA-small molecule screens reported to date. The screen employed a Tat peptide displacement assay (Z score=0.71), included several steps to prevent false positives and false negatives (see Methods), and yielded a total of seven new hits (Supplementary Table 1 ) representing two novel small molecule classes that bind TAR and inhibit the TAR-Tat interaction (Supplemental Fig. 1 ). Such low hit rates (~0.007%) are typical for large RNAsmall molecule screens 7 .
The ~100,000 molecule library used in HTS was augmented with an additional 240 molecules previously shown to bind HIV-1 TAR ( Supplementary Table 2 ) and the combined library used in EBVS. The additional hits included 81 aminoglycosides and aminoglycoside conjugates as well as a diverse set of 159 small molecules including derivatives of beta-carboline, quinolone, diphenylfuran, phenothiazine and many others. This is by far the largest and most diverse set of experimentally verified binders and non-binders used to evaluate VS against any RNA target. EBVS was carried out by computationally docking the virtual small molecule library to a recently reported high-resolution dynamic ensemble of HIV-1 TAR RNA 14 . The ensemble contains twenty conformers that describe the various TAR conformations sampled in the unbound state ( Fig.   1b ) 14 . Compared to the previous TAR ensemble used in VS 9, 13 (see E1 below), this improved ensemble was determined using four rather than two sets of RDCs, obtained using a variableelongation approach 21 . In addition, a longer MD simulation (8.2 µs versus 80 ns) was used to generate the pool of starting TAR conformations 14 . Using the docking program Internal Coordinate Mechanics (ICM) 22 , each small molecule was docked against each of the twenty TAR conformers using binding pockets defined by the ICM PocketFinder module (Fig. 1b ). The docking scores computed for a given small molecule across the twenty TAR conformers were averaged assuming a Boltzmann distribution (see Methods).
To evaluate the ability of EBVS to enrich true hits while discriminating against non-hits, we used the EBVS ranked scores to compute a ROC curve, which compares the fraction of hits correctly identified (sensitivity) versus the fraction of non-hits incorrectly selected (1-specificity) at all possible docking score cutoffs. The ROC AUC describes the global enrichment of true binders with AUC=1.0 representing perfect enrichment and AUC=0.5 representing random selection of hits and non-hits.
Strikingly, EBVS globally enriches the compound library (247 hits and ~100,000 non-hits) with a ROC AUC=0.87 ( Fig. 1c ). We find strong early enrichment such that we would have identified 47% of hits after screening only 2% of non-hits (ROC (2%) =47%) ( Fig. 1c ). This corresponds to a hit rate of 5.6% compared to 0.2% had the whole library been screened. This level of enrichment was robustly observed across the different categories of experimentally verified hits ( Fig. 1d ) including aminoglycosides, non-aminoglycosides, and compounds with demonstrated cell-based activity (Supplementary Table 2 ). These levels of enrichment are comparable to best-case results when docking to known bound structures of RNA or protein 23, 24 .
By comparison, docking to individual TAR conformers either from the NMR ensemble (AUC= 0.56-0.79) or selected randomly (see E3 below) from the MD generated pool (AUC= 0.38-0.63) leads to a precipitous drop in enrichment ( Fig. 1e ). This trend is observed across all molecule categories ( Fig. 1f ) and highlights the importance of docking to an experimentally informed ensemble. Docking predicts relatively uniform binding to the twenty TAR conformers, indicating that all conformers in the ensemble contribute to the docking scores across the library. Interestingly, we observe conformer-specific enrichment in subsets of molecules within the library (Fig. 1g ). For example, conformers 1 and 2 enrich for both aminoglycoside and non-aminoglycoside hits, conformer 13 enriches for aminoglycoside hits, and conformers 19 and 20 enrich for the 14 cell-active hits.
Next, we asked whether the accuracy of the TAR ensemble was an important determinant of the docking predictions. We repeated EBVS using four additional (E1-E4) twenty-member TAR ensembles that have variable levels of accuracy as evaluated based on their ability to predict the four NMR RDC datasets 14 (Fig. 2a ). The parent ensemble (E0) predicts the four RDC datasets with RMSD = 4.0 Hz 14 . By comparison, E1 was determined using only two RDC datasets and a shorter MD simulation and predicts all four RDC datasets with RMSD = 7.1 Hz 13 . E2 and E3 were constructed by randomly selecting conformers from two different MD pools (RMSD = 8.6 and 11.0 Hz, respectively) while E4 was deliberately selected (see Methods) to poorly satisfy the RDCs (RMSD = 18.0 Hz).
Significantly, there was a strong correlation between the quality of the ensemble and the EBVS enrichment as measured by the ROC AUC ( Fig. 2b ) and ROC (2%) (Fig. 2c ) values. These trends were generally observed across different types of hits ( Fig. 2d-e ).
Next, we asked whether EBVS correctly predicts the small molecule bound TAR conformations for six TAR complexes for which high-resolution NMR structures have previously been reported: arginine (1ARJ), acetylpromazine (1LVJ), neomycin B (1QD3), RBT203 (1UUD), RBT158 (1UUI), and RBT550 (1UTS). Figure 3a compares the NMR structures to the EBVS top-scoring conformations over twenty repeated docking runs. While comparison of structures is complicated by the fact that TAR is known to retain a high degree of conformational flexibility when bound to small molecules [25] [26] [27] , qualitatively, we observe good agreement between the NMR and the EBVS-predicted bound TAR conformations ( Fig. 3a ). We find more variability in the ligand placement for docking than for NMR structures, but in general, docking correctly places molecules near the bulge-expanded major groove ( Fig. 3a) . The one exception is neomycin B; docking predicts binding to either the major or minor groove of the bulge or upper stem whereas it binds to the minor groove of the lower stem in the NMR structure, which is unusual since most aminoglycosides bind the RNA major groove 28 .
Studies have shown that ncRNAs can adopt structures that vary with respect to the global orientation of helical domains when bound to different small molecules 18, 25, 29 . We therefore examined if EBVS correctly predicts the variations in the TAR inter-helical structure when bound to the six small molecules. We compared the inter-helical Euler angles (α h β h γ h ) 30 describing the bend (β h ) and twist (α h +γ h ) angles between the two TAR helices. For all molecules, the EBVS predicted inter-helical Euler angles are in quantitative agreement with those observed in the bound NMR structures (Fig. 3a) . The EBVS predicted TAR structures are biased towards the NMR bound structures relative to all twenty conformers in the parent E0 ensemble, indicating that docking enriches for accurate bound TAR conformations (Fig 3a) . In contrast, the predicted bound structures obtained by applying EBVS to the randomly selected E3 ensemble show significantly reduced agreement with the NMR structures particularly for RBT550, RBT158 and acetylpromazine ( Supplementary Fig. 6 ). Similar results were obtained when increasing the thoroughness used in docking ( Supplementary Fig. 7 ).
We confirmed these findings by evaluating the agreement between the EBVS-predicted structures and RDCs previously measured for two of the TAR-small molecule complexes (argininamide 26 and acetylpromazine 27 ). These RDCs were not used in the NMR structure determination. This analysis could not be performed for neomycin B, for which there are also available RDCs, because docking predicted more than one small molecule bound conformation, which complicates analysis of the RDCs (see Methods). The docking predicted structures satisfy the RDCs to a comparable degree as do the high-resolution NMR structures of the TAR complexes ( Fig.   3b and Supplementary Table 3 ). Applying EBVS to the randomly selected E3 ensemble shows less favorable agreement with the measured RDCs of the bound complex, particularly for acetylpromazine ( Fig. 3b ). These results indicate that EBVS can allow the identification of small molecules that target specific RNA conformations within an ensemble, potentially enabling targeted conformational modulation of RNA with small molecules 5 .
In conclusion, EBVS significantly enriches true TAR hits including compounds with documented cell-based activities out of a large pool of ~100,000 non-hits. This result is unlikely to be coincidental since we observe that docking predicts bound conformations that agree with experimental data including NMR structures and NMR RDCs of TAR-ligand complexes. Finally, we show a direct correlation between the accuracy of the unbound TAR ensemble and the quality of 
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ONLINE METHODS

Library composition
The small molecule library used in experimental HTS consisted of 103,498 drug-like small molecules that were available at the Center for Chemical Genomics (CCG), University of Michigan, Ann Arbor. 100,000 molecules were synthetic organic molecules with drug-like properties purchased and saved in sdf file format that were previously reported to bind TAR in vitro (Supplementary Table  2 ). These molecules were identified through a literature search of TAR binders. Peptide and metalbinding molecules were excluded. For papers reporting many chemically similar molecules, only the tightest binding derivatives were included to maintain chemical diversity in our library. The protonation states of small molecules were predicted at pH 7.4 using the Major Microspecies module in the Calculator Plugin (ChemAxon).
Preparation of HIV-1 TAR RNA
HIV-1 TAR RNA (Fig. 1a) for NMR studies and experimental assays was prepared by in vitro transcription using DNA template containing the T7 promoter (Integrated DNA Technologies). DNA template was annealed at 50 µM DNA in 3 mM MgCl 2 by heating to 95°C for 5 min and cooling on ice for 30 min. The transcription reaction was carried out at 37°C for 12 hours with T7 RNA polymerase (New England BioLabs) in the presence of 13 
Preparation of HIV-1 Tat peptide
The Tat peptide used in HTS, (5-FAM)-AAARKKRRQRRRAAA-Lys(TAMRA), was purchased from LifeTein (Hillsborogh, NJ). The peptide was purified by HPLC and analyzed by Electrospray Ionization Mass Spectrometry; purity was > 95%. The peptide was stored at -20°C as a 100 µM stock solution in Tris-HCl assay buffer and diluted to 60 nM with Tris-HCl assay buffer for use in HTS.
High throughput screening assay
HTS utilized a previously described TAR-Tat displacement assay 31 that relies on the fact that the Tat peptide is highly flexible when free is solution and becomes structured upon binding to TAR [32] [33] [34] . When the Tat peptide is flexible, its two terminal fluorophores, fluorescein and TAMRA, interact and their fluorescence is quenched. Alternatively, in its extended form bound to TAR, the fluorophores are held at a distance allowing fluorescence resonance energy transfer (FRET) from fluorescein to TAMRA. Thus, as inhibitor displaces Tat, there is a decrease in fluorescence signal (excitation: 485 nm, emission: 590 nm).
High throughput screening
The workflow for HTS is shown in Supplementary Figure 1 Assay mixtures were incubated at room temperature for 10-15 minutes prior to fluorescence measurements using a Pherastar plate reader (BMG Labtech). Each plate during HTS contained 16 wells of TAR and Tat without molecule to serve as the negative control and 16 wells of Tat only to serve as the positive control. With these controls, the Z-factor 35 was calculated for each microplate; the average Z-factor throughout the screening campaign was 0.71.
Dose Response Assays
A total of 267 molecules with reproducible activity were tested in a dose response assay and those with IC 50 values below 100 µM were considered hits. Dose-response assays were performed such that the final assay concentrations were 50 nM TAR, 20 nM Tat, and 1-1000 µM molecule in Tris-HCl assay buffer. Assays were performed in parallel with and without 100-fold excess bulk yeast tRNA to test specificity and in the absence of RNA (Tat only) to measure background signal. There were 137 molecules that caused fluorescence intensity change with Tat alone, suggesting they bound Tat; these were removed from further analysis. Assays were performed in opaque 384-well microplates and read with a Clariostar plate reader (BMG Labtech). Fluorescence signal was normalized to the highest intensity after subtracting background signal. Dose response curves were fit to Equation 1 with OriginPro (OrginLab) using the instrumental weighting method. Equation 2 was used to obtain IC 50 values.
where A 1 and A 2 are the lowest and highest signals, respectively; p is the hill slope; and log(x 0 ) is the logarithm to base 10 of the concentration at half response. All variables were allowed to float during the fit. Assays were measured in triplicate and the standard deviation is reported.
Validation of Hits
The 17 small molecule hits from the dose response assays were re-purchased and re-tested for activity in addition to 56 molecules with chemical similarity to these hits, defined as having >80% similarity based on sphere exclusion clustering performed with JKlustor package (ChemAxon Nine molecules were inactive in both the displacement assay and NMR when retested with fresh molecule, suggesting that the original activity was due to contamination or degradation. One of the 56 molecules with chemical similarity to the hits was active in both the displacement assay and NMR, despite not being identified as a hit in the primary screen. Three molecules had activity in the assay, but did not bind based on NMR chemical shift titrations. Inspection of the Tat-only control for these molecules suggest that they likely bind Tat rather than TAR in the displacement assay ( Supplementary Fig. 5 ). These should have been identified earlier in the workflow, but the fluorescence change in the presence of Tat may not have been large enough. Overall, seven molecules were confirmed to bind TAR RNA based on their activity in the TAR-Tat displacement assay ( Supplementary Fig. 1b) and their ability to induce chemical shift perturbations in the TAR NMR spectra ( Supplementary Fig. 1c ).
HTS hit molecules
The seven novel confirmed HTS hits fall into two general scaffolds; five of the hits share an anthraquinone scaffold with two sites of derivatization while the other two molecules share similar geometries with napthyl and quinazoline cores (Supplementary Table 1 ). All anthraquinone derivatives maintain their IC 50 in the presence of 100-fold excess tRNA, suggesting they are specific for TAR ( Supplementary Table 1 ). Several additional anthraquinone molecules with minor differences to the five hits did not bind TAR ( Supplementary Fig. 2 ). The fact that small structural changes can ablate binding is consistent with the hit molecules making specific interactions with TAR. Interestingly, the anthraquinone hits and chemically similar molecules exhibited a change in color from orange to blue when diluted from 100% DMSO to an aqueous solution, likely due to DMSO reacting with the anthraquinone to form DMSO-anthraquinone, as described previously 39 . All experiments were performed with the derivatives in the blue state. The second class of molecules has much poorer activity in the presence of tRNA, suggesting that they are not specific for TAR ( Supplementary Table   1 ). This lack of specificity is likely due to the positive charges on these molecules, which would interact non-specifically with the RNA backbone.
The addition of the small molecule hits to TAR resulted in large chemical shift perturbations or line broadening in several residues throughout TAR ( Supplementary Fig. 1c-f ). As expected, hits with similar chemical structures induce similar chemical shift perturbations indicating that they interact with TAR using similar binding modes ( Supplementary Fig. 1c-d ). There are however two interesting exceptions. One of the five anthraquinone molecules, CCG-133905, induces significantly more broadening consistent with tighter binding, although other factors such as aggregation could induce the broadening ( Supplementary Fig. e ). The anthraquinone molecule, CCG-133994, which contains an ester and an amine, induces chemical shift perturbations that are distinct from the other anthraquinone molecules, suggesting a distinct binding mode for this molecule ( Supplementary Fig.  f ). Furthermore, NMR reveals that this molecule is in slow exchange, which is in agreement with the fact that it is the tightest binder in the TAR-Tat displacement assays.
Identification of false negatives in HTS
Molecules that were insoluble in the assay conditions or that had fluorescence interference with the Tat peptide would have been excluded from the HTS workflow and this may represent a possible source of false negatives in our dataset. To investigate this possibility, we selected nine molecules in the top ~3% of docking scores and tested them for TAR binding using NMR. Three of the nine molecules did in fact bind TAR under NMR conditions ( Supplementary Fig. 4b ). Closer analysis revealed different factors led to the exclusion of these small molecules from HTS during the primary screen. One molecule, CCG-39701, was insoluble in DMSO but was active in the assay when dissolved in water ( Supplementary Fig. 4a ). The other two molecules, CCG-208298 and CCG-100975, had fluorescence interference at high concentration preventing determination of an accurate IC 50 ( Supplementary Fig. 4a ). These results highlight a weakness of HTS, which is the presence false negatives, which we recognize is a source of uncertainty in our analysis. To avoid biasing the results, these molecules were not included in the ROC analysis.
Virtual Screening
VS was performed using the docking program Internal Coordinate Mechanics (ICM, Molsoft) 22 .
Docking was set up as described previously 19 . Briefly, each of the 20 conformers of the TAR dynamic ensemble 34 was uploaded to ICM in PDB format and converted to ICM objects using the default options (waters deleted and hydrogens optimized). Binding pockets were identified with the ICM PocketFinder Module using a tolerance value of 4.6. Receptor maps were generated to include all atoms within 5 Å of the predicted binding pockets with atom occupancy weighted. Docking was run with a thoroughness value of 1, flexible ring sampling level 2, and covalent geometry relaxed. For high-thoroughness docking, the thoroughness value was increased to 20, and all other parameters remained the same.
Ensemble-Based Docking Scores
The docking scores provided by ICM represent predicted binding energies in kcal/mol. For each molecule, the fractional population of all 20 TAR conformers was calculated using the Boltzmann distribution (Eq. 3). The population of each conformer was multiplied by its docking score and these values were summed over all conformers to calculate the population-weighted score of each molecule (Eq. 4).
Where p i is the population of conformer i, ε i is the docking score of conformer i, k is the Boltzmann constant, T is temperature (298 K), and M is the number of conformers in the ensemble.
Receiver Operator Characteristic Curves
OriginPro (OriginLab) was used to plot receiver operator characteristic curves using Equations 5 and 6 and to calculate the area under the curve using the trapezoidal rule. Details on these equations can be found at (http://www.originlab.com/doc/Origin-Help/ROCCurve-Algorithm). where n is the number of true negatives (TN), true positives (TP), false negatives (FN) or false positives (FP) at any given score threshold value.
TAR Ensembles of Variable Accuracy
The RDC-derived TAR ensembles (E0 and E1) were determined as reported previously 13, 14 .
The randomly selected ensembles (E2 and E3) were constructed by using a random number generator to randomly select 20 structures from the two pools of TAR conformations generated using MD simulations 13, 14 containing 10,000 and 80,000 conformations, respectively. An ensemble that poorly agrees with all four RDC data sets (E4) was generated using a sample and select (SAS)
Monte Carlo selection scheme to maximize the χ 2 function assessing the agreement between measured and predicted RDCs (Eq. 7) 13 .
Where i runs over all the RDCs measured for the different constructs j and δ is the weight used to normalize different RDC data sets, and is set at one tenth of the range of RDCs measured for each TAR construct 14 . D exp are the experimentally measured RDCs and D calc are the predicted RDCs that were calculate by PALES 40,41 as described below.
The quality of the various TAR ensembles used in this study was determined by evaluating how well they agree with four sets of RDC data measured on variably elongated TAR RNA molecules as described previously 14 . Briefly, the program PALES 40, 41 was used to calculate predicted RDCs based on the structures in the ensemble, after in silico elongation as described previously 14 . A scaling factor was used to account for variations in experimental conditions. The predicted RDCs are averaged for all structures of the ensemble assuming equal probabilities (Eq. 8).
where k runs over the N conformers of the ensemble, λ j is the scaling factor for the j th TAR construct and D i,j is the i th coupling in the j th construct. These calculated RDCs were then compared to measured RDCs and the RMSD (Hz) was calculated.
Docking Predicted Pose Analysis
Pose analysis was carried out for six TAR binders for which there are NMR structures deposited in the PDB: arginine (1ARJ), acetylpromazine (1LVJ), neomycin B (1QD3), RBT203
(1UUD), RBT158 (1UUI), and RBT550 (1UTS) 28, [42] [43] [44] [45] . For each of these molecules, docking was repeated twenty times with thoroughness set to one (Fig. 3a) . It was also repeated five times with the thoroughness value increased to twenty, meaning the time spent docking each ligand was increased twenty-fold (Supplemental Fig. 7) . The inter-helical angles (α h , β h , γ h ) were computed for each ensemble conformer as well as for each model of the NMR structures using an in-house software as described previously 29 . For this calculation, the lower helix was defined as C19-G43, A20-U42 and G21-C41 and the upper helix was defined by G26-C39, A27-U38 and G28-C37. For docking results, the inter-helical angles were population-weighted based on docking scores and averaged over all runs. The inter-helical angles of the NMR structures were averaged over all models. Repeating this analysis using five docking runs with increased thoroughness improved the agreement between interhelical angles for RBT158, RBT550, acetylpromazine and arginine, had little effect in the case of neomycin B, and worsened the agreement for the twist angle in the case of RBT203 ( Supplementary   Fig. 7) . Interestingly, neomycin B and RBT203 were the least consistent in conformer selection across the 5 runs of docking.
We also compared the docking predicted poses and NMR structures to published RDCs of the ligand-TAR complex for arginine 26 and acetylpromazine 27 . This analysis was done only for the most favored conformer from high-thoroughness docking over the 5 runs: conformer 8 for arginine (>86% populated in 4/5 runs) and conformer 3 for acetylpromazine (>72% populated in 4/5 runs). For the random ensemble, E3, conformer 4 was selected for arginine (>99% populated for 4/5 runs) and conformer 3 was selected for acetylpromazine (>99% populated for 5/5 runs). Likewise, only the lowest energy NMR structure was used for this analysis. The program RAMAH 46 was used to compare these structures to the published RDC data sets. Briefly, RAMAH determines the best-fit order tensor for a given structure and set of RDCs using single value decomposition, it then uses this order tensor to calculate RDCs and reports the RMSD (Hz) between calculated and experimental RDCs. RDCs of N-H bond vectors and for residues in the bulge, loop, or terminal ends were excluded. 
